Plasma 3,3',5-Triiodo-L-thyronine [T3] level mirrors changes in tumor markers in two cases of metastatic cancer of the breast and pancreas treated with exogenous L-T3.

Abstract

Preclinical studies have attributed 3,3',5-triiodo-L-thyronine (T3) a direct negative effect on tumor progression, as well as chemosensitizing, differentiating and immunomodulatory properties. On the other hand, L-thyroxine (T4), via a thyroid hormone receptor on plasma membrane integrin αvβ3, promotes solid tumor growth and neoangiogenesis, therefore lowering endogenous T4 reduces tumor growth rate. We present the case of two patients with metastatic triple negative breast cancer and metastatic pancreatic cancer respectively, who benefit of the sole treatment with antithyroid drugs and exogenous administration of T3 (liothyronine). In these cases tumor growth was accompanied by T3 depletion in plasma, which may represent a novel marker for progression.

• Authors: Alejandro Rodríguez-Molinero, Aleck Hercbergs, Manuel Sarrias, Antonio Yuste
• Journal: Cancer biomarkers : section A of Disease markers (Cancer Biomark) Vol. 21 Issue 2 Pg. 433-438 (Feb 06 2018) ISSN: 1875-8592 [Electronic] Netherlands
• PMID: 29125479 (Publication Type: Case Reports, Journal Article)

Chemical References

• Biomarkers, Tumor
• Triiodothyronine

Topics

• Aged
• Aged, 80 and over
• Biomarkers, Tumor (blood)
• Female
• Humans
• Neoplasm Metastasis
• Pancreatic Neoplasms (blood, drug therapy, pathology)
• Triiodothyronine (administration & dosage, blood)
• Triple Negative Breast Neoplasms (blood, drug therapy, pathology)